244 related articles for article (PubMed ID: 22258475)
1. Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer?
Guckenberger M; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Grills IS
J Thorac Oncol; 2012 Mar; 7(3):542-51. PubMed ID: 22258475
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
3. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
[TBL] [Abstract][Full Text] [Related]
4. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.
Grills IS; Hope AJ; Guckenberger M; Kestin LL; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Belderbos J
J Thorac Oncol; 2012 Sep; 7(9):1382-93. PubMed ID: 22843086
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
6. Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.
Yamamoto T; Kadoya N; Shirata Y; Koto M; Sato K; Matsushita H; Sugawara T; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Ito K; Katagiri Y; Takeda K; Jingu K
Radiat Oncol; 2015 Feb; 10():35. PubMed ID: 25886315
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system.
Katoh N; Soda I; Tamamura H; Takahashi S; Uchinami Y; Ishiyama H; Ota K; Inoue T; Onimaru R; Shibuya K; Hayakawa K; Shirato H
Radiat Oncol; 2017 Jan; 12(1):3. PubMed ID: 28057036
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy for central lung tumors, yes we can!
Korzets Ceder Y; Fenig E; Popvtzer A; Peled N; Kramer MR; Saute M; Bragilovsky D; Schochat T; Allen AM
Radiat Oncol; 2018 Apr; 13(1):77. PubMed ID: 29695273
[TBL] [Abstract][Full Text] [Related]
9. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Xiao Y; Grills IS
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1074-81. PubMed ID: 23154077
[TBL] [Abstract][Full Text] [Related]
10. Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months.
Navarro-Martin A; Aso S; Cacicedo J; Arnaiz M; Navarro V; Rosales S; de Blas R; Ramos R; Guedea F
J Thorac Oncol; 2016 Jul; 11(7):1101-11. PubMed ID: 27103512
[TBL] [Abstract][Full Text] [Related]
11. No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236.
Stanic S; Paulus R; Timmerman RD; Michalski JM; Barriger RB; Bezjak A; Videtic GM; Bradley J
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1092-9. PubMed ID: 24661663
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.
Grills IS; Mangona VS; Welsh R; Chmielewski G; McInerney E; Martin S; Wloch J; Ye H; Kestin LL
J Clin Oncol; 2010 Feb; 28(6):928-35. PubMed ID: 20065181
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes in Early-stage NSCLC Treated with Stereotactic Body Radiotherapy Versus Surgical Resection.
Kastelijn EA; El Sharouni SY; Hofman FN; Van Putte BP; Monninkhof EM; Van Vulpen M; Schramel FM
Anticancer Res; 2015 Oct; 35(10):5607-14. PubMed ID: 26408733
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer.
Matsuo Y; Shibuya K; Nagata Y; Takayama K; Norihisa Y; Mizowaki T; Narabayashi M; Sakanaka K; Hiraoka M
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1104-11. PubMed ID: 20472343
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
[TBL] [Abstract][Full Text] [Related]
17. Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.
Shaverdian N; Veruttipong D; Wang J; Kupelian P; Steinberg M; Lee P
Clin Lung Cancer; 2017 Mar; 18(2):e137-e142. PubMed ID: 27908620
[TBL] [Abstract][Full Text] [Related]
18. Preliminary report of late recurrences, at 5 years or more, after stereotactic body radiation therapy for non-small cell lung cancer.
Matsuo Y; Shibuya K; Nagata Y; Norihisa Y; Narabayashi M; Sakanaka K; Ueki N; Mizowaki T; Hiraoka M
J Thorac Oncol; 2012 Feb; 7(2):453-6. PubMed ID: 22252562
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.
Taremi M; Hope A; Dahele M; Pearson S; Fung S; Purdie T; Brade A; Cho J; Sun A; Bissonnette JP; Bezjak A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):967-73. PubMed ID: 21377293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
